[go: up one dir, main page]

ECSP088456A - Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias - Google Patents

Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias

Info

Publication number
ECSP088456A
ECSP088456A EC2008008456A ECSP088456A ECSP088456A EC SP088456 A ECSP088456 A EC SP088456A EC 2008008456 A EC2008008456 A EC 2008008456A EC SP088456 A ECSP088456 A EC SP088456A EC SP088456 A ECSP088456 A EC SP088456A
Authority
EC
Ecuador
Prior art keywords
cancer
treatment
pirimidn
tiofen
amina
Prior art date
Application number
EC2008008456A
Other languages
English (en)
Inventor
Q May Wang
Karl Robert Dahnke
Ho-Shen Lin
Michael Enrico Richett
Chuan Shih
Bo Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP088456A publication Critical patent/ECSP088456A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula I: útil en el tratamiento de cáncer y enfermedades inflamatorias.
EC2008008456A 2005-11-18 2008-05-16 Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias ECSP088456A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
ECSP088456A true ECSP088456A (es) 2008-06-30

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008456A ECSP088456A (es) 2005-11-18 2008-05-16 Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias

Country Status (27)

Country Link
US (1) US7547691B2 (es)
EP (1) EP1989200B1 (es)
JP (1) JP2009516697A (es)
KR (1) KR100990771B1 (es)
CN (1) CN101309918B (es)
AR (1) AR057911A1 (es)
AT (1) ATE437873T1 (es)
AU (1) AU2006337626B2 (es)
BR (1) BRPI0618245A2 (es)
CA (1) CA2629336A1 (es)
CR (1) CR9947A (es)
DE (1) DE602006008187D1 (es)
DK (1) DK1989200T3 (es)
EA (1) EA014426B1 (es)
EC (1) ECSP088456A (es)
ES (1) ES2329085T3 (es)
IL (1) IL190489A0 (es)
MA (1) MA30053B1 (es)
NO (1) NO20082594L (es)
PE (1) PE20070833A1 (es)
PL (1) PL1989200T3 (es)
PT (1) PT1989200E (es)
SI (1) SI1989200T1 (es)
TN (1) TNSN08227A1 (es)
TW (1) TW200800201A (es)
WO (1) WO2007092095A2 (es)
ZA (1) ZA200803940B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51423B (sr) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. Benzoimidazol-2-il pirimidini i pirazini kao modulatori histaminskog h4 receptora
WO2008011557A2 (en) * 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
MX2009006635A (es) 2006-12-21 2009-06-30 Lilly Co Eli Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer.
AU2007334039B2 (en) 2006-12-21 2012-02-16 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer
BRPI0811433A2 (pt) 2007-05-16 2016-03-22 Lilly Co Eli compostos do tipo triazolil aminopirimidina
US8114872B2 (en) 2007-05-16 2012-02-14 Eli Lilly And Company Triazolyl aminopyrimidine compounds
PT2310012E (pt) 2008-06-30 2015-04-02 Janssen Pharmaceutica Nv Processo para a preparação de derivados de pirimidina substituída
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011022473A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
MX2012012502A (es) 2010-04-27 2013-01-18 Hutchison Medipharma Ltd Compuestos pirimidinil indol.
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
JP6250561B2 (ja) 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物およびそれらの使用方法
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
EP3573964A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3630745A2 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Covalent inhibitors of kras
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
JP4932735B2 (ja) * 2004-12-17 2012-05-16 アムジエン・インコーポレーテツド アミノピリミジン化合物および使用方法

Also Published As

Publication number Publication date
ZA200803940B (en) 2009-09-30
CR9947A (es) 2008-11-28
BRPI0618245A2 (pt) 2011-08-23
EA014426B1 (ru) 2010-12-30
DK1989200T3 (da) 2009-11-09
AU2006337626B2 (en) 2012-03-22
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
AU2006337626A8 (en) 2008-06-19
JP2009516697A (ja) 2009-04-23
EP1989200B1 (en) 2009-07-29
PE20070833A1 (es) 2007-08-27
SI1989200T1 (sl) 2009-12-31
US7547691B2 (en) 2009-06-16
TNSN08227A1 (en) 2009-10-30
AR057911A1 (es) 2007-12-26
WO2007092095A2 (en) 2007-08-16
TW200800201A (en) 2008-01-01
DE602006008187D1 (de) 2009-09-10
US20080306082A1 (en) 2008-12-11
PT1989200E (pt) 2009-10-12
MA30053B1 (fr) 2008-12-01
PL1989200T3 (pl) 2009-12-31
WO2007092095A3 (en) 2007-11-08
NO20082594L (no) 2008-06-10
IL190489A0 (en) 2008-11-03
ATE437873T1 (de) 2009-08-15
EP1989200A2 (en) 2008-11-12
CN101309918A (zh) 2008-11-19
CN101309918B (zh) 2010-12-29
KR100990771B1 (ko) 2010-10-29
ES2329085T3 (es) 2009-11-20
KR20080059451A (ko) 2008-06-27
EA200801362A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
ECSP088456A (es) Derivados de [4-(benzo[b]tiofen-2-il)pirimidn-2il]-amina como inhibidores ikk-beta para el tratamiento de cancer y enfermedades inflamatorias
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
ECSP109882A (es) Derivados de 1-cianociclopropilo como inhibidores de la catepsina k
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
CR20140392A (es) Dihidropirazolonas sustituidas
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
SMP201100019B (it) Composti organici
ECSP11010778A (es) Amidofenoxiindazoles útiles como inhibidores de c-met
UY33000A (es) Derivados de sulfonamida heterocíclicos
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
CR11452A (es) 5-((3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino)-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiflamatorios
UY32748A (es) 2-carboxamida-cicloamino-ureas
CU20120085A7 (es) Derivados de sulfamidas heterocíclicas
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
NZ596158A (en) Thioxanthene derivatives for the treatment of infectious diseases
DOP2011000197A (es) Derivados de arilciclopropilacetamida utiles como activadores de glucoquinasa